Melatonin in cardiovascular disease

Expert Opinion on Investigational Drugs

Volumn 21, Issue 11, 2012, Pages 1593-1596

  Dominguez Rodriguez, Alberto ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

Author keywords

Agomelatine; Cardiac pathophysiology; Cardiovascular disease; Circadin; Melatonin receptor; Ramelteon

Indexed keywords

AGOMELATINE; FREE RADICAL; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; RAMELTEON; REACTIVE OXYGEN METABOLITE;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CIRCADIAN RHYTHM; CIRCADIAN RHYTHM SLEEP DISORDER; CORONARY ARTERY ATHEROSCLEROSIS; DEPRESSION; ELECTRON TRANSPORT; HUMAN; HYPERTENSION; INSOMNIA; NONHUMAN; OXIDATIVE STRESS; PINEAL BODY; REPERFUSION INJURY; REVIEW; SEASONAL AFFECTIVE DISORDER;

ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; FREE RADICAL SCAVENGERS; HUMANS; MELATONIN; MOLECULAR TARGETED THERAPY; REACTIVE OXYGEN SPECIES; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2;

EID: 84867502399     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.716037     Document Type: Review

References (18)

1. Lopez Ad, Murray CC. The global burden of disease: 1990-2020. Nat Med 1998;4:1241-3
2. Tengattini S, Reiter RJ, Tan DX, et al. Cardiovascular diseases: protective effects of melatonin. J Pineal Res 2008;44:16-25
3. Petrosillo G, Di Venosa N, Pistolese M, et al. Protective effect of melatonin against mitochondrial dysfunction associated with cardiac ischemiareperfusion: role of cardiolipin. FASEB J 2006;20:269-76
4. Papaharalambus CA, Griendling KK. Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc Med 2007;17:48-54
5. Alvarez Y, Perez-Giron JV, Hernanz R, et al. Losartan reduces the increased participation of cyclooxygenase-2-derived products in vascular responses of hypertensive rats. J Pharmacol Exp Ther 2007;321:381-8
6. Nava M, Quiroz Y, Vaziri N, Rodriguez-Iturbe B. Melatonin reduces renal interstitial inflammation and improves hypertension in spontaneously hypertensive rats. Am J Physiol Renal Physiol 2003;284:F447-54
7. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007;49:241-8
8. Dominguez-Rodriguez A, Abreu-Gonzalez P, Arroyo-Ucar E, Reiter RJ. Decreased level of melatonin in serum predicts left ventricular remodelling after acute myocardial infarction. J Pineal Res 2012; in press
9. Galano A, Tan DX, Reiter RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011;51:1-16
10. Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P. The role of melatonin in acute myocardial infarction. Front Biosci 2012;17:2433-41
11. Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter RJ. Melatonin and cardiovascular disease: myth or reality? Rev Esp Cardiol 2012;65:215-18
12. Dominguez-Rodriguez A, Abreu-Gonzalez P, Sanchez-Sanchez JJ, et al. Melatonin and circadian biology in human cardiovascular disease. J Pineal Res 2010;49:14-22
13. Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter RJ. Clinical aspects of melatonin in the acute coronary syndrome. Curr Vasc Pharmacol 2009;7:367-73
14. Reiter RJ, Tan DX, Paredes SD, Fuentes-Broto L. Beneficial effects of melatonin in cardiovascular disease. Ann Med 2010;42:276-85
15. Lee YM, Chen HR, Hsiao G, et al. Protective effects of melatonin on myocardial ischemia/reperfusion injury in vivo. J Pineal Res 2002;33:72-80
16. Kilic U, Yilmaz B, Ugur M, et al. Evidence that membrane-bound G protein-coupled melatonin receptors MT1 and MT2 are not involved in the neuroprotective effects of melatonin in focal cerebral ischemia. J Pineal Res 2012;52:228-35
17. Dubocovich ML, Delagrange P, Krause DN, et al. International union of basic and clinical pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev 2010;62:343-80
18. Hardeland R. Investigational melatonin receptor agonists. Expert Opin Investig Drugs 2010;19:747-64